News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>UBS: GALAXY ENT (00027.HK) 4Q25 Adj. EBITDA in Line; Rating Buy
GALAXY ENT (00027.HK)'s 4Q25 adjusted EBITDA was approx. $4.3 billion, up about 33% YoY and about 29% QoQ, according to UBS' research report. Adjusted for VIP hold, the EBI...
Reset
Send
The window will close in 5 seconds
<Research>UBS: GALAXY ENT (00027.HK) 4Q25 Adj. EBITDA in Line; Rating Buy
Close
Recommend
11
Positive
11
Negative
3
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

GALAXY ENT (00027.HK)  0.000 (0.000%)    Short selling $61.73M; Ratio 80.280%   's 4Q25 adjusted EBITDA was approx. $4.3 billion, up about 33% YoY and about 29% QoQ, according to UBS' research report. Adjusted for VIP hold, the EBITDA would be approx. $3.6 billion, up 9% YoY and 7% QoQ, in line with estimation.

Furthermore, GALAXY ENT announced a final DPS of $0.8, higher than the market consensus of $0.65, bringing the full-year DPS to $1.5, equivalent to a dividend payout ratio of about 61%, compared to 50% in 2024. Therefore, the broker rated GALAXY ENT at Buy, with a target price of $46.9.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)

Related News Citi: Macau Mar GGR Beats Expectations; Sees Apr GGR at 21B Macau Patacas

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.